Researchers at Cincinnati Children's have reported that a newer class of cancer drugs shrank the nerve tumors caused by neurofibromatosis type 1 at least as effectively as the MEK inhibitors currently approved for the condition, in a study conducted entirely in mice.
The findings were published on September 2, 2026, in the journal Science Advances by Nancy Ratner and nine co-authors. The full paper reports that KRAS is required for these tumors to form and that blocking it also reduced tumors that had already developed.
